

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Title: Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Publication year: 2020

Journal: Allergy

Authors: Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Society: European Academy of Allergy and Clinical Immunology

Origin country: International (Europe)

Target countries: Europe

DOI: 10.1111/all.14439

PMID: 32511784

Source: <https://pubmed.ncbi.nlm.nih.gov/32511784/>

Allergy Allergy 3812 phebblackwell 7804028 ALL Allergy 0105-4538 1398-9995
pmc-is-collection-domain yes pmc-collection-title Wiley - PMC COVID-19 Collection PMC7300843
PMC7300843.1 7300843 7300843 32511784 10.1111/all.14439 ALL14439 1 Eaaci Position Paper
Eaaci Position Papers Diagnosis and management of the drug hypersensitivity reactions in
Coronavirus disease 19: An EAACI Position Paper GELINCİK et al. Gelincik Asl
<https://orcid.org/0000-0002-3524-9952> 1 gelincikasli@hotmail.com Brockow Knut
<https://orcid.org/0000-0002-2775-3681> 2 Çelik Gülfem E. <https://orcid.org/0000-0001-8654-513X> 3
Doña Inmaculada <https://orcid.org/0000-0002-5309-4878> 4 5 Mayorga Cristobalina
<https://orcid.org/0000-0001-8852-8077> 6 Romano Antonino <https://orcid.org/0000-0002-5029-4372>
7 8 Soyer Özge <https://orcid.org/0000-0002-7444-251X> 9 Atanaskovic Markovic Marina
<https://orcid.org/0000-0003-1354-6072> 10 Barbaud Annick <https://orcid.org/0000-0001-8889-1589>
11 12 Torres Maria Jose <https://orcid.org/0000-0001-5228-471X> 13 1 Department of Internal
Medicine Division of Immunology and Allergic Diseases Istanbul Faculty of Medicine Istanbul
University Istanbul Turkey 2 Department of Dermatology and Allergy Biederstein Faculty of
Medicine Technical University of Munich Munich Germany 3 Department of Chest Diseases
Division of Immunology and Allergy Ankara University School of Medicine Ankara Turkey 4 Allergy
Unit Hospital Regional Universitario de Málaga ARADyAL Málaga Spain 5 Allergy Research
Group Instituto de Investigación Biomédica de Málaga IBIMA ARADyAL Málaga Spain 6
Research Laboratory IBIMA Regional University Hospital of Malaga UMA ARADyAL Malaga
Spain 7 IRCCS Oasi Maria S.S. Troina Italy 8 Fondazione Mediterranea G.B. Morgagni Catania
Italy 9 Pediatric Allergy Department Hacettepe University School of Medicine Ankara Turkey 10
Faculty of Medicine University Children's Hospital University of Belgrade Belgrade Serbia 11
Department of Dermatology and Allergology, Tenon Hospital (AP HP) Sorbonne Universities,
Pierre et Marie Curie University Paris France 12 Institut Pierre Louis d'Epidémiologie et de Santé
Publique AP HP Sorbonne Université Paris France 13 Allergy Unit Regional University Hospital of
Malaga IBIMA UMA BIONAND ARADyAL Malaga Spain * Correspondence Asl Gelincik,
Department of Internal Medicine, Division of Immunology and Allergic Diseases Istanbul University,
Istanbul Faculty of Medicine, Turgut Özal Millet Cad, 34390, Fatih, Istanbul. Email:
gelincikasli@hotmail.com 01 7 2020 11 2020 75 11 359779 10.1111/all.v75.11 2775 2793 31 5
2020 07 5 2020 01 6 2020 01 07 2020 18 06 2020 25 04 2024 © 2020 EAACI and John Wiley and
Sons A/S. Published by John Wiley and Sons Ltd. This article is being made freely available
through PubMed Central as part of the COVID-19 public health emergency response. It can be
used for unrestricted research re-use and analysis in any form or by any means with
acknowledgement of the original source, for the duration of the public health emergency. Abstract
Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human
coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of

clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes
pmc-prop-open-access no pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed
no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no
pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no
pmc-prop-preprint no pmc-prop-in-epmc yes source-schema-version-number 2.0 cover-date
November 2020 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC
version:6.1.7 mode:remove_FC converted:12.07.2022 Gelincik A , Brockow K , Çelik GE , et al.
Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An
EAACI Position Paper . Allergy . 2020 ; 75 : 2775 – 2793 . 10.1111/all.14439 32511784
PMC7300843